Ganciclovir Shortage Update: What Patients Need to Know in 2026

If you've been prescribed ganciclovir and are struggling to fill it, you're not imagining the problem. While ganciclovir is not currently in an active FDA drug shortage, this specialty antiviral is a sterile injectable with limited distribution — meaning localized supply gaps at pharmacies and infusion centers are an ongoing reality for many patients.

Here's everything you need to know as a patient about the current supply situation in 2026, what factors contribute to access problems, and what you can do to protect your treatment.

Current Ganciclovir Shortage Status (2026)

As of early 2026, ganciclovir IV injection (500 mg vials, generic formulation) is not listed in the FDA Drug Shortage Database as an active shortage. The national supply is considered adequate. However, this does not mean every pharmacy or hospital has it on their shelves today.

Because ganciclovir IV is a specialty sterile injectable — not a high-volume drug like a blood pressure medication or antibiotic — individual pharmacies and infusion centers may run low or out of stock without a formal FDA shortage being declared. Sterile injectables are among the most vulnerable drug categories to localized supply disruptions, as documented by ASHP year after year.

Why Supply Disruptions Happen Even Without an Official Shortage

Several structural factors make ganciclovir prone to access problems even when total national supply is technically sufficient:

Few manufacturers: The generic ganciclovir IV market is served by a small number of manufacturers, meaning any production disruption has a large impact on supply.

Specialty distribution: Ganciclovir IV is distributed primarily through hospital purchasing groups and specialty distributors, not general pharmacy wholesalers.

Low demand relative to manufacturing complexity: Producing sterile injectable vials requires significantly more investment and quality oversight than making oral tablets.

Patient population size: The number of patients needing ganciclovir IV at any given time is relatively small compared to common medications, meaning pharmacies have less incentive to keep large safety stocks.

What Is the History of Ganciclovir Supply Problems?

Ganciclovir has a long history of supply challenges going back decades. The drug was originally approved in 1988-1989, during the AIDS epidemic, when CMV retinitis was a common and devastating opportunistic infection. In those years, demand was high and supply chains were not always adequate.

In more recent years, as effective HIV antiretrovirals reduced the incidence of CMV retinitis in the developed world, demand for ganciclovir shifted toward transplant medicine. Organ transplant volumes have grown substantially, keeping demand relevant — but the drug remains a specialty product with a limited number of suppliers.

What Patients Can Do Right Now

If you are having trouble filling your ganciclovir prescription, here are concrete steps to take:

Contact your prescriber immediately. Do not delay treatment. Your infectious disease doctor, HIV specialist, or transplant physician can help identify available supply and may be able to switch you to valganciclovir (Valcyte) if appropriate.

Ask about specialty pharmacies and home infusion. These channels have better access to ganciclovir IV than retail pharmacies.

Use medfinder to search pharmacies near you. medfinder calls pharmacies on your behalf to check which ones have ganciclovir in stock. This can save hours of phone calls, especially for patients who are already dealing with a serious illness.

Ask your hospital pharmacy directly. If you were treated in a hospital, ask whether their pharmacy can dispense ganciclovir for outpatient or home use through their outpatient pharmacy program.

Do not stop treatment without medical guidance. Interrupting ganciclovir therapy — particularly for CMV retinitis — can allow the infection to progress rapidly and cause vision loss. Your provider may be able to bridge you with valganciclovir until supply is restored.

Monitoring the Situation Going Forward

Patients on long-term ganciclovir therapy or those who anticipate needing it for transplant prophylaxis should proactively work with their prescribing team to ensure supply. Providers should be aware of their institutions' current stock levels. For more detail on how providers can plan ahead, see our post on the ganciclovir shortage guide for providers.